Research programme: receptor tyrosine kinase inhibitors - GlaxoSmithKline

Drug Profile

Research programme: receptor tyrosine kinase inhibitors - GlaxoSmithKline

Alternative Names: REarranged in Transfection tyrosine kinase inhibitors; GSK 1838705A; GW-578257A; RET inhibitors; RET tyrosine kinase inhibitors; VEGFR-2/TIE-2 inhibitors - GSK

Latest Information Update: 18 Apr 2011

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Benzimidazoles; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Insulin-like growth factor-I receptor antagonists; Receptor protein-tyrosine kinase antagonists; TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 22 Apr 2009 Preclinical pharmacodynamics data on receptor tyrosine kinase inhibitors presented at the 100th Annual Meeting of the American Association for Cancer Research
  • 05 May 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top